期刊
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 63, 期 15, 页码 1473-1479出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2014.01.018
关键词
subcutaneous ICD; sudden cardiac death; transvenous ICD
资金
- Medtronic
The recently commercially available subcutaneous implantable cardioverter-defibrillator (S-ICD) uses a completely subcutaneous electrode configuration to treat potentially lethal ventricular tachyarrhythmia. Clinical trials have proven its effectiveness in detecting and treating ventricular fibrillation and tachycardia. The S-ICD offers the advantage of eliminating the need for intravenous and intracardiac leads and their associated risks and shortcomings. However, its major disadvantage is its inability to provide bradycardia rate support and antitachycardia pacing to terminate ventricular tachycardia. This paper discusses the S-ICD clinical trials and advantages and disadvantages of this novel technology to help the physician identify its role and select candidate patients who will benefit from this device. (C) 2014 by the American College of Cardiology Foundation
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据